Ondine Biomedical Inc. (AIM:OBI)
London
· Delayed Price · Currency is GBP · Price in GBX 10.50
-0.50 (-4.76%)
Jun 13, 2025, 4:35 PM GMT+1
Ondine Biomedical Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2.05 | 1.2 | 0.64 | 2.57 | 1.79 | Upgrade
|
| Revenue Growth (YoY) | 70.32% | 88.56% | -75.17% | 43.44% | 16.84% | Upgrade
|
| Cost of Revenue | 0.73 | 0.5 | 0.35 | 1.32 | 1.14 | Upgrade
|
| Gross Profit | 1.32 | 0.7 | 0.29 | 1.25 | 0.65 | Upgrade
|
| Selling, General & Admin | 11.01 | 9.8 | 12.31 | 13.33 | 12.04 | Upgrade
|
| Research & Development | 9.22 | 5.14 | 6.28 | 4.98 | 3.31 | Upgrade
|
| Operating Expenses | 20.77 | 15.51 | 19.05 | 18.77 | 16.52 | Upgrade
|
| Operating Income | -19.44 | -14.81 | -18.76 | -17.52 | -15.87 | Upgrade
|
| Interest Expense | -0.03 | -0.05 | -0.03 | -0.01 | -0.49 | Upgrade
|
| Interest & Investment Income | 0.03 | 0.24 | 0.19 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.04 | -0.14 | 0.64 | 0.19 | 0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.3 | 0 | -1.33 | -1.63 | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | -19.1 | -14.75 | -19.29 | -18.98 | -16.27 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.1 | -0.08 | - | - | Upgrade
|
| Other Unusual Items | - | 0.44 | - | -31.11 | - | Upgrade
|
| Pretax Income | -19.1 | -14.41 | -19.37 | -50.09 | -16.27 | Upgrade
|
| Net Income | -19.1 | -14.41 | -19.37 | -50.09 | -16.27 | Upgrade
|
| Net Income to Common | -19.1 | -14.41 | -19.37 | -50.09 | -16.27 | Upgrade
|
| Shares Outstanding (Basic) | 275 | 197 | 195 | 80 | 71 | Upgrade
|
| Shares Outstanding (Diluted) | 275 | 197 | 195 | 80 | 71 | Upgrade
|
| Shares Change (YoY) | 39.31% | 1.30% | 144.34% | 12.69% | 761.95% | Upgrade
|
| EPS (Basic) | -0.07 | -0.07 | -0.10 | -0.63 | -0.23 | Upgrade
|
| EPS (Diluted) | -0.07 | -0.07 | -0.10 | -0.63 | -0.23 | Upgrade
|
| Free Cash Flow | -15.5 | -13.83 | -16.66 | -12.62 | -6.36 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.07 | -0.09 | -0.16 | -0.09 | Upgrade
|
| Gross Margin | 64.47% | 58.44% | 44.98% | 48.81% | 36.24% | Upgrade
|
| Operating Margin | -948.95% | -1230.67% | -2940.91% | -681.98% | -886.15% | Upgrade
|
| Profit Margin | -932.06% | -1198.01% | -3036.36% | -1949.59% | -908.49% | Upgrade
|
| Free Cash Flow Margin | -756.47% | -1149.63% | -2610.66% | -491.13% | -355.00% | Upgrade
|
| EBITDA | -19.24 | -14.59 | -18.54 | -17.24 | -14.91 | Upgrade
|
| D&A For EBITDA | 0.21 | 0.21 | 0.22 | 0.28 | 0.96 | Upgrade
|
| EBIT | -19.44 | -14.81 | -18.76 | -17.52 | -15.87 | Upgrade
|
| Advertising Expenses | 0.13 | 0.18 | 0.23 | 0.14 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.